The North America genotyping market was valued at US$ 12,044.57 million in 2023 and is expected to reach US$ 62,900.63 million by 2031; it is estimated to record a CAGR of 23.0% from 2023 to 2031.
Use in Diagnosis of Genetic and Rare Diseases Fuels North America Genotyping Market
According to the World Health Organization (WHO), ~35 million new cancer cases are likely to occur in 2050, a 77% increase from the corresponding 20 million cases in 2022. In 2022, the Alzheimer’s Association stated that the number of people living with Alzheimer’s in the US is rapidly increasing. The disease affects more than 6 million Americans from all age groups. As per the association’s estimates, 6.5 million Americans aged more than 65 suffered from Alzheimer's as of 2022, and 73% of this population was aged 75 or older. As per a study published in the Journal of Health Monitoring, up to 300 million people worldwide suffer from rare diseases. Although individual diseases are rare, they collectively pose significant challenges to the global healthcare system.
Since cancer, Alzheimer’s disease, and rare diseases are difficult to identify clinically, genotyping stands as the backbone of diagnostic testing in the population. DNA sequences obtained from genotyping can be compared to sample or reference sequences to determine variations. Genotyping is also employed to detect single-nucleotide polymorphisms (SNPs), which are minor variations in genetic complement within the population. The human genome has nearly 660 million SNPs, which makes them the most widespread genetic variation. Moreover, by comparing polymorphisms in healthy and diseased populations, genome-wide association studies (GWAS) can uncover links between common illnesses and SNPs. GWAS can untangle the molecular mechanisms in underlying disease states by finding probable causes. SNPs are even present in single-celled organisms, such as bacteria. SNP genotyping can discriminate between microorganism isolates and could even be accustomed to identifying antibiotic-resistant strains. SNP-based strain detection has a significant impact on each pharmaceutical and clinical analysis, and it has also been used in infectious disease epidemiology.
North America Genotyping Market Overview
The North America genotyping market is segmented into the US, Canada, and Mexico. Increasing adoption of technologically advanced products and solutions, and surging research and development activities are the factors benefiting the genotyping market in this region. Moreover, government-led programs such as the “All of Us Research Program,” initiatives by various genomic communities, and the increasing awareness of genotyping services are the key drivers of the market expansion across North America.
North America Genotyping Market Revenue and Forecast to 2031 (US$ Million)
North America Genotyping Market Segmentation
The North America genotyping market is categorized into product type, technology, application, end user, and country.
Based on product type, the North America genotyping market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held the largest market share in 2023.
By technology, the North America genotyping market is categorized into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held the largest market share in 2023.
Based on application, the North America genotyping market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held the largest market share in 2023.
In terms of end user, the North America genotyping market is bifurcated into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.
By country, the North America genotyping market is segmented into the US, Canada, and Mexico. The US dominated the North America genotyping market share in 2023.
Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, Thermo Fisher Scientific Inc, BioTek Instruments, Inc, TRIMGEN CORPORATION, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA. are some of the leading companies operating in the North America genotyping market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 12,044.57 Million |
| Market Size by 2031 | US$ 62,900.63 Million |
| CAGR (2023 - 2031) | 23.0% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product Type
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
The North America Genotyping Market is valued at US$ 12,044.57 Million in 2023, it is projected to reach US$ 62,900.63 Million by 2031.
As per our report North America Genotyping Market, the market size is valued at US$ 12,044.57 Million in 2023, projecting it to reach US$ 62,900.63 Million by 2031. This translates to a CAGR of approximately 23.0% during the forecast period.
The North America Genotyping Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Genotyping Market report:
The North America Genotyping Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Genotyping Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Genotyping Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For North America Genotyping Market
